Clinical Trials & Research
Search Clinical Trials
|Title||Veliparib and Carboplatin in Treating Women With HER2-Negative Metastatic Breast Cancer|
|Description||The purpose of this trial is to study the side effects and best dose of veliparib when given with carboplatin and to see how well they work in treating women with HER2-negative metastatic breast cancer.|
Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Veliparib may help carboplatin work better by making tumor cells more sensitive to the drug.
|Eligibility Criteria||To be eligible for this study, patients must meet several criteria, including but not limited to the following:|
* Patient must be 18 Years and older
*Patient must have histologically or cytologically proven metastatic or locally advanced inoperable breast cancer that fulfills one of the following three criteria:
-Triple-negative breast cancer
-ER and/or PR positive, HER2 negative if their tumors have been -shown to be deficient for the FA pathway, based on FATSI immunofluorescence screening.
* Patient is able to swallow pills
|Principal Investigator||Joseph Sparano, MD|
|Contact Name||Karen Fehn, RN|
|Current Trial Type||Interventional|